AC Immune SA EBIT

AC Immune SA (ACIU) currently reports a EBIT of $-66M as of March 2026. That compares with $-50M in the prior-year period — down 31.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore AC Immune SA's EBIT history and peer comparisons.

AC Immune SA's EBIT decreased from $-50M to $-66M — a 31.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AC Immune SA's EBIT of $-66M is lower than the Healthcare sector average of $22B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AC Immune SA reported $-66M in EBIT as of March 2026. That compares with $-50M in the prior-year period — down 31.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-66M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for AC Immune SA, and consider following ACIU for alerts when major investors trade the stock.